Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021079158 - PROSTATE CANCER DETECTION METHODS

Publication Number WO/2021/079158
Publication Date 29.04.2021
International Application No. PCT/GB2020/052706
International Filing Date 23.10.2020
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/154
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
154Methylation markers
Applicants
  • CANCER RESEARCH TECHNOLOGY LIMITED [GB]/[GB]
Inventors
  • ATTARD, Gerhardt
  • CREMASCHI, Paolo
  • WETTERSKOG, Daniel
Agents
  • ABEL & IMRAY
Priority Data
1915469.924.10.2019GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PROSTATE CANCER DETECTION METHODS
(FR) MÉTHODES DE DÉTECTION DU CANCER
Abstract
(EN)
The present invention provides methods of detecting, screening, monitoring, staging, classification, selecting treatment for, ascertaining whether treatment is working in, and/or prognostication of prostate cancer comprising determining the average methylation ratio at 10 or more genomic regions as set out in the application, and associated methods of selecting a treatment or ascertaining whether a treatment is effective. The present invention also provides a method for determining a solid cancer circulating free DNA (cfDNA) methylome signature for use in the detecting, screening, monitoring, staging, classification, selecting treatment for, ascertaining whether treatment is working in, and/or prognostication of the solid cancer in a sample obtained from a subject comprising determining the average methylation ratio at 10 or more genomic regions as set out in the application.
(FR)
La présente invention concerne des méthodes de détection, de criblage, de surveillance, de détermination du stade, de classification, de sélection de traitement pour, vérifier si le traitement donne des résultats, et/ou de pronostic du cancer de la prostate consistant à déterminer le rapport de méthylation moyen à 10 ou plus de régions génomiques telles que définies dans l'application, et des méthodes associées de sélection d'un traitement ou de détermination de l'efficacité d'un traitement. La présente invention concerne également une méthode de détermination d'une signature méthylome d'ADN libre circulant (cfDNA) dans une tumeur solide destinée à être utilisée dans la détection, le criblage, la surveillance, la détermination du stade, la classification, la sélection du traitement pour, vérifier si le traitement donne des résultats, et/ou de pronostic de tumeur solide dans un échantillon provenant d'un sujet consistant à déterminer le rapport de méthylation moyen à 10 ou plus de régions génomiques telles que définies dans l'application.
Latest bibliographic data on file with the International Bureau